141109-83-3

Upstream product

• 100-44-7 benzyl chloride 
• 62517-34-4 ethyl 2-hydroxy-3-(4-hydroxyphenyl)propionate 
• 100-39-0 benzyl bromide 
• 95332-25-5 3-(4-Benzyloxy-phenyl)-oxirane-2-carboxylic acid ethyl ester 

Downstream Products

• 223127-72-8 ethyl 3-(4-benzyloxyphenyl)-2-(4-tert-butylphenoxy)propionate 
• 223126-28-1 3-(4-benzyloxyphenyl)-2-ethoxypropanoic acid ethyl ester 
• 197299-11-9 2-phenoxy-3-(4-benzyloxyphenyl)propionic acid ethyl ester 
• 223127-91-1 ethyl 3-(4-benzyloxyphenyl)-2-(4-trifluoromethoxyphenoxy)propionate 
• 223127-75-1 ethyl 3-(4-benzyloxyphenyl)-2-(4-fluorophenoxy)propionate 
• 223127-94-4 ethyl 3-(4-benzyloxyphenyl)-2-(4-cyanophenoxy)propionate 
• 197299-17-5 ethyl 3-(4-benzyloxyphenyl)-2-methanesulfonyloxypropionate 
• 710327-26-7 ethyl (R)-2-(4-tert-butylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 
• 710327-30-3 ethyl (S)-2-(4-tert-butylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 
• 223125-72-2 ethyl 2-(4-tert-butylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 
• 710327-14-3 ethyl (R)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 
• 710327-19-8 ethyl (S)-2-(4-isopropylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 

Relevant academic research and scientific papers

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation

Type-2 diabetes (T2D) is a complex metabolic disease characterized by insulin resistance in the liver and peripheral tissues accompanied by a defect in pancreatic β-cell. Since their discovery three subtypes of Peroxisomes Proliferators Activated Receptors were identified namely PPARα, PPARγ and PPARβ/(δ). We were interested in designing novel PPARγ selective agonists and/or dual PPARα/γ agonists. Based on the typical topology of synthetic PPAR agonists, we focused our design approach on 4,4-dimethyl-1,2,3,4-tetrahydroquinoline as novel cyclic tail.

Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents

We previously reported the identification of novel oximes having 5-benzyl-2,4-thiazolidinedione with antihyperglycemic activity. We now report the synthesis and biological activity of a novel series of oximes and amides having α-substituted-β-phenylpropionic acids. In this series, we obtained potent PPARα/γ dual agonist (S)-9d, with which activation of PPARα and PPARγ was considerably more potent than that of the reference compounds GW9578 22 and rosiglitazone 3, respectively. This means (S)-9d is of the strongest class of PPARα/γ dual agonists. In the course of this study, we also obtained 8h, which indicated potent plasma glucose lowering effect in spite of weak PPARα/γ agonistic activity.

Amidocarboxylic acid derivatives

Amidocarboxylic acid derivatives of the formula: wherein R1 represents a hydrogen atom, etc.; R2 represents an alkylene group; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; X represents a substituted or unsubstituted aryl group, etc.,; Y represents an oxygen atom, etc.; Z represents an alkylene group, etc.; and W represents an alkyl group, etc.; and pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof are useful as the active ingredient of pharmaceutical compositions. They may be used to treat specified diseases, including diabetes mellitus, hyperlipemia, arteriosclerosis, hypertension, etc.

MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT

The present invention relates to a pharmaceutical composition comprising an insulin sensitizer and a diuretic which can prevent or treat side effects such as edema, cardiac enlargement, body fluid retension or hydrothorax caused by administration of an insulin sensitizer.